(Q28375856)

2

0 references

G Lewis

3

0 references

R Pietras

4

0 references

M Beryt

5

0 references

M Sliwkowski

6

0 references

D Coombs

7

0 references

D Baly

8

0 references

F Kabbinavar

9

0 references

D Slamon

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

10

0 references

language of work or name

English

0 references

publication date

1 April 1999

0 references

published in

Oncogene

0 references

volume

18

0 references

page(s)

2241-51

0 references

issue

13

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Comparison of in vitro cell cytotoxic assays for tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Identification of heregulin, a specific activator of p185erbB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Computerized determination of growth kinetic curves and doubling times from cells in microculture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

Determination of cell number in monolayer cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

Expression of C-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for C-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1202526

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1202526

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

3980864

1001624052

0 references

3980864

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference